GSK:LON
GSK plc
GBXÂ 1Â 805,00
arrow_downward
-1,47%(-27,00) 1D
1 Okt., 09:00:35 GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
GBXÂ 1Â 810,50
High
GBXÂ 1Â 810,50
Low
GBXÂ 1Â 792,50
Mkt. cap
73,02Â mjd
Avg. vol.
5,43Â m
Volume
720,69Â k
Dividend
3,77%
Quarterly dividend
GBXÂ 17,00
Ex-dividend date
13 Aug. 2026
P/E ratio
15,30
52-wk high
GBXÂ 2Â 282,00
52-wk low
GBXÂ 1Â 590,50
EPS
GBXÂ 1,18
Shares outstanding
4,05Â mjd
No. of employees
67Â k
Open
GBXÂ 1Â 810,50
High
GBXÂ 1Â 810,50
Low
GBXÂ 1Â 792,50
Mkt. cap
73,02Â mjd
Avg. vol.
5,43Â m
Volume
720,69Â k
Dividend
3,77%
Quarterly dividend
GBXÂ 17,00
Ex-dividend date
13 Aug. 2026
P/E ratio
15,30
52-wk high
GBXÂ 2Â 282,00
52-wk low
GBXÂ 1Â 590,50
EPS
GBXÂ 1,18
Shares outstanding
4,05Â mjd
No. of employees
67Â k
News stories
From web sources and news partners
AD HOC NEWS
·
3 uur gelede
GSK Pharma stock enters a results blackout before Q2 FY27
AD HOC NEWS
·
10 uur gelede
GSK stock: company announces oncology deal and positive Jideytro data
AD HOC NEWS
·
11 uur gelede
Wave Life Sciences stock gets a USD 12.0 million GSK boost
Traders Union
·
17 uur gelede
What's behind GSK's latest share pullback?
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8Â k
Founded27 Des. 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com